From Wikipedia, the free encyclopedia
Jump to: navigation, search

Antiprotozoal agents (ATC code: ATC P01) is a class of pharmaceuticals used in treatment of protozoan infection.

Protozoans have little in common with each other (for example, Entamoeba histolytica, an unikont eukaryotic organism, is less closely related to Naegleria fowleri, a bikont eukaryotic organism, than it is to Homo sapiens, which belongs to the unikont phylogenetic group) and so agents effective against one pathogen may not be effective against another. However, metronidazole is selective for anaerobic organisms, and so it is effective against many (though not all) of these pathogens.

They can be grouped by mechanism[1] or by organism.[2] Recent papers have also proposed the use of viruses to treat infections caused by protozoa.[3][4]



  1. ^ Cynthia R. L. Webster (15 June 2001). Clinical pharmacology. Teton NewMedia. pp. 86–. ISBN 978-1-893441-37-8. Retrieved 2 May 2010. 
  2. ^ Anthony J. Trevor; Bertram G. Katzung; Susan B. Masters (11 December 2007). Katzung & Trevor's pharmacology: examination & board review. McGraw-Hill Professional. pp. 435–. ISBN 978-0-07-148869-3. Retrieved 2 May 2010. 
  3. ^ Keen, E. C. (2013). "Beyond phage therapy: Virotherapy of protozoal diseases". Future Microbiology 8 (7): 821–823. doi:10.2217/FMB.13.48. 
  4. ^ Hyman, P.; Atterbury, R.; Barrow, P. (2013). "Fleas and smaller fleas: Virotherapy for parasite infections". Trends in Microbiology 21 (5): 215–220. doi:10.1016/j.tim.2013.02.006. PMID 23540830.